Physician profile
Sonal Jain
NPI 1770600538
$1,266.96
in general payments reported to CMS, 2019-2025
22 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $182 · 2021: $315 · 2022: $200 · 2023: $112 · 2024: $258 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $199.74 | 2021-2025 | Qelbree, Qelbree |
| Alexion Pharmaceuticals, INC. | $198.73 | 2020-2023 | Koselugo |
| Pfizer INC. | $121.37 | 2022-2024 | |
| Corium, LLC | $117.76 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $96.26 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $75.94 | 2020-2022 | |
| Adlon Therapeutics L.P. | $74.70 | 2020-2021 | |
| Alk-Abello, INC | $60.10 | 2024 | Odactra, Ragwitek, Grastek |
| Genentech USA, INC. | $40.91 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $40.73 | 2020-2022 | |
| Verrica Pharmaceuticals INC. | $32.83 | 2024 | Ycanth |
| Cranial Technologies, INC | $27.84 | 2021-2025 | Doc Band |
| Kyowa Kirin, INC. | $25.49 | 2025 | |
| Vertical Pharmaceuticals, LLC | $24.33 | 2025 | Relexxii |
| Tris Pharma INC | $19.05 | 2025 | Dyanavel Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $18.18 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $17.33 | 2025 | Neffy |
| Seqirus USA INC | $16.80 | 2024 | Flucelvax |
| Neos Therapeutics, LP | $16.06 | 2025 | Cotempla Xr-Odt |
| Glaxosmithkline, LLC. | $15.97 | 2021 | |
| Cipher Pharmaceuticals US LLC | $13.72 | 2025 | Natroba, Spinosad |
| Aytu Biopharma, INC. | $13.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonal Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.